lansoprazole has been researched along with Antibiotic-Associated Colitis in 6 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 7.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 3.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilcox, CM | 1 |
| Martin, T | 1 |
| Phadnis, M | 1 |
| Mohnen, J | 1 |
| Worthington, J | 1 |
| Hirschowitz, BI | 1 |
| Kaur, S | 2 |
| Vaishnavi, C | 2 |
| Prasad, KK | 2 |
| Ray, P | 2 |
| Kochhar, R | 2 |
| Rai, R | 1 |
| Rai, S | 1 |
| Kubo, N | 1 |
| Kochi, S | 1 |
| Ariyama, I | 1 |
| Murata, M | 1 |
| Furusyo, N | 1 |
| Hayashi, J | 1 |
| Lau, CF | 1 |
| Hui, PK | 1 |
| Fung, TT | 1 |
| Tung, SY | 1 |
| Wong, AM | 1 |
| Loo, CK | 1 |
| Lam, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
6 other studies available for lansoprazole and Antibiotic-Associated Colitis
| Article | Year |
|---|---|
Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti | 2008 |
Effect of Lactobacillus acidophilus & epidermal growth factor on experimentally induced Clostridium difficile infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Animals; Cecum; Clostridioides difficile; Colon | 2011 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocol | 2002 |
[Pseudomembranous colitis after Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2006 |
Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Animals; Anti-Bacterial Agents; Bacterial Toxin | 2007 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2001 |